(0.40%) 5 038.66 points
(0.45%) 38 074 points
(0.73%) 15 720 points
(-0.37%) $78.71
(4.61%) $2.02
(-0.01%) $2 310.70
(0.79%) $26.96
(0.79%) $962.45
(0.28%) $0.936
(0.30%) $11.06
(0.32%) $0.801
(-1.30%) $92.05
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 4.21%
Live Chart Being Loaded With Signals
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide...
Stats | |
---|---|
Šios dienos apimtis | 1.20M |
Vidutinė apimtis | 1.32M |
Rinkos kapitalizacija | 68.37B |
EPS | $0 ( 2024-02-01 ) |
Kita pelno data | ( $0 ) 2024-08-01 |
Last Dividend | $0.950 ( 2024-03-07 ) |
Next Dividend | $0 ( N/A ) |
P/E | 54.16 |
ATR14 | $0.586 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Garrison Michael David | Sell | 1 715 | Common Stock |
2024-04-04 | Neal Shana Carol | Sell | 1 921 | Common Stock |
2024-03-14 | Spoerel Thomas J | Sell | 282 | Common Stock |
2024-03-01 | Garrison Michael David | Sell | 178 | Common Stock |
2024-03-01 | Spoerel Thomas J | Sell | 36 | Common Stock |
INSIDER POWER |
---|
68.11 |
Last 100 transactions |
Buy: 255 635 | Sell: 56 729 |
Tūris Koreliacija
Becton Dickinson and Co Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
AGQ | 0.901 |
SLV | 0.889 |
SIVR | 0.888 |
PSLV | 0.881 |
SO | 0.88 |
KMB | 0.88 |
LLY | 0.864 |
TDI | 0.855 |
NVS | 0.853 |
PG | 0.833 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
ZSL | -0.861 |
INSW | -0.854 |
AYI | -0.853 |
NM | -0.838 |
TNP | -0.83 |
STAR | -0.827 |
TEX | -0.823 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Becton Dickinson and Co Koreliacija - Valiuta/Žaliavos
Becton Dickinson and Co Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $19.37B |
Bruto pelnas: | $8.17B (42.17 %) |
EPS: | $4.97 |
FY | 2023 |
Pajamos: | $19.37B |
Bruto pelnas: | $8.17B (42.17 %) |
EPS: | $4.97 |
FY | 2022 |
Pajamos: | $18.87B |
Bruto pelnas: | $8.48B (44.92 %) |
EPS: | $5.93 |
FY | 2021 |
Pajamos: | $20.25B |
Bruto pelnas: | $9.43B (46.56 %) |
EPS: | $6.92 |
Financial Reports:
No articles found.
Becton Dickinson and Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.870 (N/A) |
$0.910 (N/A) |
$0.910 (N/A) |
$0.910 (N/A) |
$0.910 (N/A) |
$0.950 (N/A) |
$0.950 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0213 | 1973-02-28 |
Last Dividend | $0.950 | 2024-03-07 |
Next Dividend | $0 | N/A |
Payout Date | 2024-03-29 | |
Next Payout Date | N/A | |
# dividends | 165 | -- |
Total Paid Out | $47.51 | -- |
Avg. Dividend % Per Year | 1.05% | -- |
Score | 4.96 | -- |
Div. Sustainability Score | 9.40 | |
Div.Growth Potential Score | 4.17 | |
Div. Directional Score | 6.78 | -- |
Year | Amount | Yield |
---|---|---|
1973 | $0.0213 | 0.94% |
1974 | $0 | 0.00% |
1975 | $0 | 0.00% |
1976 | $0 | 0.00% |
1977 | $0 | 0.00% |
1978 | $0 | 0.00% |
1979 | $0 | 0.00% |
1980 | $0 | 0.00% |
1981 | $0 | 0.00% |
1982 | $0 | 0.00% |
1983 | $0.0525 | 2.00% |
1984 | $0.0716 | 3.11% |
1985 | $0.0750 | 3.10% |
1986 | $0.0829 | 2.18% |
1987 | $0.0940 | 1.52% |
1988 | $0.109 | 1.74% |
1989 | $0.124 | 1.99% |
1990 | $0.134 | 1.76% |
1991 | $0.143 | 1.57% |
1992 | $0.150 | 1.85% |
1993 | $0.166 | 1.75% |
1994 | $0.187 | 2.13% |
1995 | $0.210 | 1.78% |
1996 | $0.232 | 1.25% |
1997 | $0.229 | 1.08% |
1998 | $0.295 | 1.21% |
1999 | $0.339 | 0.81% |
2000 | $0.365 | 1.43% |
2001 | $0.374 | 1.12% |
2002 | $0.384 | 1.18% |
2003 | $0.439 | 1.43% |
2004 | $0.614 | 1.53% |
2005 | $0.738 | 1.35% |
2006 | $0.869 | 1.47% |
2007 | $0.995 | 1.45% |
2008 | $1.156 | 1.37% |
2009 | $1.327 | 1.95% |
2010 | $1.493 | 1.95% |
2011 | $1.669 | 2.02% |
2012 | $1.800 | 2.48% |
2013 | $1.981 | 2.56% |
2014 | $2.18 | 2.05% |
2015 | $2.40 | 1.76% |
2016 | $2.64 | 1.83% |
2017 | $2.87 | 1.78% |
2018 | $2.95 | 1.39% |
2019 | $3.02 | 1.41% |
2020 | $3.12 | 1.17% |
2021 | $3.28 | 1.34% |
2022 | $3.50 | 1.42% |
2023 | $3.68 | 1.44% |
2024 | $0.950 | 0.39% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
ZTR | Dividend Royal | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0625 | 1.500 | 8.75 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0233 | 1.200 | 9.22 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0474 | 1.500 | -0.584 | -0.876 | [0.1 - 1] |
payoutRatioTTM | 0.910 | -1.000 | 0.903 | -0.903 | [0 - 1] |
currentRatioTTM | 1.082 | 0.800 | 9.59 | 7.67 | [1 - 3] |
quickRatioTTM | 0.457 | 0.800 | -2.02 | -1.612 | [0.8 - 2.5] |
cashRatioTTM | 0.156 | 1.500 | -0.242 | -0.363 | [0.2 - 2] |
debtRatioTTM | 0.308 | -1.500 | 4.86 | -7.30 | [0 - 0.6] |
interestCoverageTTM | 8.19 | 1.000 | 8.08 | 8.08 | [3 - 30] |
operatingCashFlowPerShareTTM | 11.82 | 2.00 | 6.06 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 9.13 | 2.00 | 5.44 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.636 | -1.500 | 7.46 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.414 | 1.000 | 6.44 | 6.44 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.101 | 1.000 | 9.98 | 9.98 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.213 | 1.000 | 9.93 | 9.93 | [0.2 - 2] |
assetTurnoverTTM | 0.373 | 0.800 | -0.847 | -0.678 | [0.5 - 2] |
Total Score | 9.40 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 55.67 | 1.000 | 4.48 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0474 | 2.50 | -0.376 | -0.876 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 9.13 | 2.00 | 6.96 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.592 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 11.82 | 2.00 | 6.06 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.910 | 1.500 | 0.903 | -0.903 | [0 - 1] |
pegRatioTTM | 0.367 | 1.500 | -0.886 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.176 | 1.000 | 8.10 | 0 | [0.1 - 0.5] |
Total Score | 4.17 |
Becton Dickinson and Co
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.